New Data on the Safety of Loratadine
- First Online:
- Cite this article as:
- Van Cauwenberge, P.B. Drug Invest (1992) 4: 283. doi:10.1007/BF03259406
Since the European registration of loratadine, a significant amount of new and previously unpublished data have become available supporting the generally good tolerability profile of this nonsedating antihistamine. This report describes safety data obtained from more than 55 000 additional patients in open and controlled studies, and also describes information obtained from postmarketing surveillance data during the widespread use of this agent. These new data demonstrate that loratadine does not possess any significant CNS or anticholinergic effects and the side effects are comparable with those associated with placebo. Loratadine is apparently lacking in any unusual or serious effects and is well tolerated by a wide spectrum of patient populations, including the elderly and patients taking a variety of concomitant medications for concurrent illnesses.